期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 7, 页码 2869-2878出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01805
关键词
-
资金
- National Institutes of Health [AI084411]
- University of Tennessee
- NIH Shared Instrumentation Grant
Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gram-negative bacteria to treat and eradicate. In a cell-based screening of pleuromutilin derivatives against a drug sensitive A. baumannii strain, new molecules (2-4) exhibit bacteriostatic activity with 3.13 mu g/mL concentration and 1 shows bactericidal activity with an MBC of 6.25 mu g/mL. The pleuromutilin derivative 1 displays strong synergistic effects with doxycycline in a wide range of concentrations. A 35/1 ratio of 1 and doxycycline (1-Dox 35/1) kills drug susceptible A. baumannii with the MBC of 2.0 mu g/mL and an MDR A. baumannii with the MBC of 3.13 mu g/mL. In vitro anti-Acinetobacter activity of 1-Dox 35/1 is superior to that of clinical drugs such as tobramycin, tigecycline, and colistin. The efficacy of 1-Dox 35/1 is evaluated in a mouse septicemia model; treatment of the infected CS7BL/6 mice with 1-Dox 35/1 protects from lethal infection of A. baumannii with an ED50 value of <2.0 mg/kg.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据